{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:00:04Z","timestamp":1777496404180,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.pharep.2014.02.022","type":"journal-article","created":{"date-parts":[[2014,4,26]],"date-time":"2014-04-26T03:00:27Z","timestamp":1398481227000},"page":"565-569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of the clinical indications, adverse drug reactions, and finasteride use in patients with benign prostatic hyperplasia in Poland"],"prefix":"10.1007","volume":"66","author":[{"given":"Tomasz","family":"Z\u0105bkowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10.1016\/j.pharep.2014.02.022_bib0105","first-page":"535","article-title":"Finasteride in the treatment of patients with benign prostatic hyperplasia: a review","volume":"5","author":"Smith","year":"2009","journal-title":"Ther Clin Risk Manage"},{"key":"10.1016\/j.pharep.2014.02.022_bib0010","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1159\/000052475","article-title":"The progression of benign prostatic hyperplasia: examining the evidence and determining the risk","volume":"39","author":"Anderson","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.pharep.2014.02.022_bib0015","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJM199802263380901","article-title":"The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group","volume":"338","author":"McConnell","year":"1998","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharep.2014.02.022_bib0030","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4103\/0253-7613.75657","article-title":"Benign prostatic hyperplasia: an overview of existing treatment","volume":"43","author":"Dhingra","year":"2011","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.pharep.2014.02.022_bib0125","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1007\/s00120-012-2868-8","article-title":"Evaluation of finasteride efficacy in the treatment of benign prostatic hyperplasia","volume":"51","author":"Z\u0105bkowski","year":"2012","journal-title":"Urologe"},{"key":"10.1016\/j.pharep.2014.02.022_bib0120","first-page":"43","article-title":"A long-term pharmacotherapy of benign prostatic hyperplasia (BPH)","volume":"17","author":"Z\u0105bkowski","year":"2010","journal-title":"Czas Aptekarskie"},{"key":"10.1016\/j.pharep.2014.02.022_bib0130","doi-asserted-by":"crossref","first-page":"13453","DOI":"10.1021\/bi00041a024","article-title":"Mechanism of time-dependent inhibition of 5alpha-reductase by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies","volume":"34","author":"Tian","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharep.2014.02.022_bib0060","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4103\/0019-5359.40582","article-title":"Current status of 5\u03b1-reductase inhibitors in the treatment of benign hyperplasia of prostate","volume":"62","author":"Kumar","year":"2008","journal-title":"Indian J Med Sci"},{"key":"10.1016\/j.pharep.2014.02.022_bib0035","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1358\/dot.2002.38.12.740205","article-title":"The pathophysiology of benign prostatic hyperplasia","volume":"38","author":"Djavan","year":"2002","journal-title":"Drugs Today"},{"key":"10.1016\/j.pharep.2014.02.022_bib0070","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/0090-4295(93)90258-C","article-title":"Medical therapy for benign prostatic hyperplasia","volume":"42","author":"Lepor","year":"1993","journal-title":"Urology"},{"key":"10.1016\/j.pharep.2014.02.022_bib0065","first-page":"181","article-title":"Alpha blockers for the treatment of benign prostatic hyperplasia","volume":"9","author":"Lepor","year":"2007","journal-title":"Rev Urol"},{"key":"10.1016\/j.pharep.2014.02.022_bib0040","series-title":"Benign prostatic hyperplasia","author":"Dutkiewicz","year":"1994"},{"key":"10.1016\/j.pharep.2014.02.022_bib1065","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0022-5347(17)49698-4","article-title":"The development of human benign prostatic hyperplasia with age","volume":"132","author":"Berry","year":"1984","journal-title":"J Urol"},{"key":"10.1016\/j.pharep.2014.02.022_bib0025","first-page":"141","article-title":"BPH: Costs and treatment outcomes","volume":"12","author":"Curtis","year":"2006","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.pharep.2014.02.022_bib0090","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0025-7125(05)70159-0","article-title":"Benign prostatic hyperplasia (the aging prostate)","volume":"83","author":"Medina","year":"1999","journal-title":"Med Clin N Am"},{"key":"10.1016\/j.pharep.2014.02.022_bib0110","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharep.2014.02.022_bib0080","first-page":"182","article-title":"The long-term effects of finasteride on BPH: results of a four-year, placebo-controlled study","volume":"80","author":"McConnell","year":"1997","journal-title":"Br J Urol"},{"key":"10.1016\/j.pharep.2014.02.022_bib0055","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0090-4295(99)80191-5","article-title":"Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men","volume":"46","author":"Kirby","year":"1995","journal-title":"Urology"},{"key":"10.1016\/j.pharep.2014.02.022_bib0095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/TCRM.S86","article-title":"Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy","volume":"4","author":"Neil","year":"2008","journal-title":"Ther Clin Risk Manage"},{"key":"10.1016\/j.pharep.2014.02.022_bib0005","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/nau.20500","article-title":"LUTS treatment: future treatment options","volume":"26","author":"Andersson","year":"2007","journal-title":"Neurourol Urodyn"},{"issue":"Suppl. 3","key":"10.1016\/j.pharep.2014.02.022_bib0045","first-page":"533","article-title":"The role of combination medical therapy in benign prostatic hyperplasia","volume":"20","author":"Greco","year":"2008","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.pharep.2014.02.022_bib0100","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/j.1742-1241.2008.01880.x","article-title":"A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia","volume":"62","author":"Nickel","year":"2008","journal-title":"Int J Clin Pract"},{"issue":"1A","key":"10.1016\/j.pharep.2014.02.022_bib0020","first-page":"3","article-title":"The treatment of the patients with BPH with alpha-1-adrenolitics (Polish)","volume":"51","author":"Bor\u00f3wka","year":"1998","journal-title":"Urol Pol"},{"key":"10.1016\/j.pharep.2014.02.022_bib0050","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.juro.2008.05.004","article-title":"Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial","volume":"180","author":"Kaplan","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.pharep.2014.02.022_bib0075","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJM199608223350801","article-title":"The efficacy of terazosin, finasteride or both in benign prostatic hypertrophy","volume":"335","author":"Lepor","year":"1996","journal-title":"N Engl J Med"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114014001522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114014001522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:35:26Z","timestamp":1752611726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2014.02.022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S1734114014001522"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2014.02.022","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the clinical indications, adverse drug reactions, and finasteride use in patients with benign prostatic hyperplasia in Poland","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2014.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}